DexCom reports 15% Q2 2025 revenue growth, boosted by expanded type 2 diabetes access & product innovation. Discover their raised outlook & future plans.

Q3 2025 Management View CEO Cristiano Renno Amon reported revenues of $10.4 billion and non-GAAP earnings per share of $2.77, noting this was "near the high end of our guidance range." He highlighted ...